PMID- 28536414
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231112
IS  - 2227-9059 (Print)
IS  - 2227-9059 (Electronic)
IS  - 2227-9059 (Linking)
VI  - 3
IP  - 4
DP  - 2015 Dec 4
TI  - Enzyme-Linked Immunosorbent Spot Assay for the Detection of Wilms' Tumor 
      1-Specific T Cells Induced by Dendritic Cell Vaccination.
PG  - 304-315
LID - 10.3390/biomedicines3040304 [doi]
AB  - BACKGROUND: Despite recent advances in cancer immunotherapy and the development 
      of various assays for T cell assessment, a lack of universal standards within 
      immune monitoring remains. The objective of this study was to evaluate the 
      enzyme-linked immunosorbent spot (ELISpot) assay in comparison with major 
      histocompatibility complex-tetramer analysis in the context of dendritic cell 
      (DC)-based cancer immunotherapy. METHODS: The ELISpot assay was performed on 
      peripheral blood mononuclear cells to assess reproducibility, daily precision, 
      and linearity using HLA-A*24:02-restricted Cytomegalovirus peptide. Wilms' tumor 
      1 (WT1) antigen-specific cytotoxic T cells were then evaluated by both the 
      ELISpot assay and WT1 tetramer analysis in peripheral blood from 46 cancer 
      patients who received DC vaccinations pulsed with human leukocyte antigen 
      (HLA)-A*24:02-restricted modified WT1 peptides. RESULTS: The ELISpot assay was 
      proven to have reproducibility (coefficient of variation (CV) ranged from 7.4% to 
      16.3%), daily precision (CV ranged from 5.0% to 17.3%), and linearity (r = 
      0.96-0.98). WT1-specific immune responses were detected by the ELISpot assay in 
      34 out of 46 patients (73.9%) post-vaccination. A Spearman's rank-correlation 
      coefficient of 0.82 between the ELISpot assay and WT1 tetramer analysis was 
      obtained. CONCLUSION: This is the first report of a comparison of an ELISpot 
      assay and tetramer analysis in the context of dendritic cell (DC)-based cancer 
      immunotherapy. The ELISpot assay has reproducibility, linearity, and excellent 
      correlation with the WT1 tetramer analysis. These findings suggest that the 
      validated ELISpot assay is useful to monitor the acquired immunity by DC 
      vaccination targeting WT1.
FAU - Higuchi, Yumiko
AU  - Higuchi Y
AD  - Center for Advanced Cell Therapy, Shinshu University Hospital, Matsumoto 
      390-8621, Japan. sasa0922@shinshu-u.ac.jp.
AD  - Department of Health and Medical Sciences, Shinshu University Graduate School of 
      Medicine, Matsumoto 390-8621, Japan. sasa0922@shinshu-u.ac.jp.
FAU - Koya, Terutsugu
AU  - Koya T
AD  - Center for Advanced Cell Therapy, Shinshu University Hospital, Matsumoto 
      390-8621, Japan. koya@shinshu-u.ac.jp.
FAU - Yuzawa, Miki
AU  - Yuzawa M
AD  - Center for Advanced Cell Therapy, Shinshu University Hospital, Matsumoto 
      390-8621, Japan. m1k1yz@shinshu-u.ac.jp.
FAU - Yamaoka, Naoko
AU  - Yamaoka N
AD  - Center for Advanced Cell Therapy, Shinshu University Hospital, Matsumoto 
      390-8621, Japan. naoko4152@shinshu-u.ac.jp.
FAU - Mizuno, Yumiko
AU  - Mizuno Y
AD  - Center for Advanced Cell Therapy, Shinshu University Hospital, Matsumoto 
      390-8621, Japan. purimeron@shinshu-u.ac.jp.
FAU - Yoshizawa, Kiyoshi
AU  - Yoshizawa K
AD  - Center for Advanced Cell Therapy, Shinshu University Hospital, Matsumoto 
      390-8621, Japan. k.yoshizawa0228@gmail.com.
FAU - Hirabayashi, Koichi
AU  - Hirabayashi K
AD  - Center for Advanced Cell Therapy, Shinshu University Hospital, Matsumoto 
      390-8621, Japan. kohira@shinshu-u.ac.jp.
FAU - Kobayashi, Takashi
AU  - Kobayashi T
AD  - Shinshu Cancer Center, Shinshu University Hospital, Matsumoto 390-8621, Japan. 
      takob@shinshu-u.ac.jp.
FAU - Sano, Kenji
AU  - Sano K
AD  - Department of Laboratory Medicine, Shinshu University Hospital, Matsumoto 
      390-8621, Japan. kenjisa@shinshu-u.ac.jp.
FAU - Shimodaira, Shigetaka
AU  - Shimodaira S
AD  - Center for Advanced Cell Therapy, Shinshu University Hospital, Matsumoto 
      390-8621, Japan. shimodai@shinshu-u.ac.jp.
LA  - eng
PT  - Journal Article
DEP - 20151204
PL  - Switzerland
TA  - Biomedicines
JT  - Biomedicines
JID - 101691304
PMC - PMC5344226
OTO - NOTNLM
OT  - Wilms' tumor 1
OT  - antigen-specific cytotoxic T cells
OT  - dendritic cells
OT  - enzyme-linked immunosorbent spot assay
OT  - tetramer analysis
COIS- The authors have no commercial, proprietary, or financial interest in the 
      products or companies described in this article.
EDAT- 2015/12/04 00:00
MHDA- 2015/12/04 00:01
PMCR- 2015/12/04
CRDT- 2017/05/25 06:00
PHST- 2015/10/07 00:00 [received]
PHST- 2015/11/23 00:00 [revised]
PHST- 2015/11/27 00:00 [accepted]
PHST- 2017/05/25 06:00 [entrez]
PHST- 2015/12/04 00:00 [pubmed]
PHST- 2015/12/04 00:01 [medline]
PHST- 2015/12/04 00:00 [pmc-release]
AID - biomedicines3040304 [pii]
AID - biomedicines-03-00304 [pii]
AID - 10.3390/biomedicines3040304 [doi]
PST - epublish
SO  - Biomedicines. 2015 Dec 4;3(4):304-315. doi: 10.3390/biomedicines3040304.